期刊文献+

血脂异常的现代药物治疗 被引量:2

Modern pharmacotherapy of lipid abnormalities
下载PDF
导出
摘要 血脂异常是引起动脉粥样硬化和冠心病最重要的危险因素。近年来其治疗药物发展迅速,新药不断应用于临床。作者分别就他汀类、贝特类等八类药物对血脂异常的调脂作用,尤其对新近研究开发的药物作一综述,并对这些药物的应用进行临床评价。 Lipid abnormality is a major risk factor of atherosclerosis and coronary heart disease. Pharmacological agents used to manage lipid abnormalities have been rapidly developed in recent years. Many new drugs have shown significant effects in the regulation of lipid abnormalities. Eight groups of drugs used to regulate lipid abnormalities were outlined in this paper, and the current recommendation for regulation of lipid abnormalities with some new drugs were discussed in details.
出处 《医学研究生学报》 CAS 2005年第10期946-948,952,共4页 Journal of Medical Postgraduates
关键词 血脂异常 调脂作用 药物治疗 Lipid abnormalities Regulation of lipid abnormalities Pharmacotherapy
  • 相关文献

参考文献19

  • 1Lamarche B,Tchernof A,Moorjani S,et al.Small dense LDL particle as a predictor of ischemic heart disease in men[J].Circulation,1997,95(1):69-75.
  • 2The Scandinavian simvastatin survival study group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease;the Scandinavian simvastatin survival study 4S[J].Lancet,1994,344(8934):1383-1389.
  • 3Battula SB,Fitzsimons O,Moreno S,et al.Postprandial apolipoprotein B48 and B100-containing lipoproteins in type 2 diabetes:do stains have a specific effect on triglyceride metabolism?[J].Metabolism,2000,49(8):1049-1054.
  • 4West of Scotland coronary prevention study group.Influence of pravastatin and plasma levels on clinical events in the scotland coronary prevention study(Woscops)[J].Circulation,1998,97(15):1440-1445.
  • 5Downs JR,Clearfield M,Weis S,et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:result of AFCAPS/TexCaps[J].JAMA,1998,279(20):1615-1622.
  • 6Sacks FM,Moye LA,Davis BR,et al.Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary event in the cholesterol and recurrent events trail[J].Circulation,1998,97(15):1446-1452.
  • 7Noji Y,Higashikata T,Inazu A,et al.Long-term treatment with pitavastatin(NK-104),a new HMG-CoA reductase inhibitor,of patients with heterozygous familial hypercholesterolemia[J].Atherosclerosis,2002,163 (1):157-164.
  • 8Grundy SM,Cleeman JI,Merz NB,et al.Implications of recent clinical trials for the national cholesterol education program adult treatment panel Ⅲ guidelines[J].Circulation,2004,110(2):227-239.
  • 9Corti R,Fuster V,Fayad ZA,et al.Lipid lowering by simvastatin induces regression of human atherosclerotic lesions:two years′follow-up by high resolution noninvasive magnetic resonance imaging[J].Circulation,2002,106(23):2884-2887.
  • 10Zhou MS,Jaimes EA,Raij L.Atorvastatin prevents end-organ injury in salt-sensitive hypertension[J].Hypertension,2004,44(2):186-190.

二级参考文献30

共引文献110

同被引文献10

  • 1赵文新,季红赞.血脂异常的药物治疗进展与临床评价[J].中国药房,2005,16(10):785-787. 被引量:8
  • 2张勇,曾小鸿.血脂紊乱和调血脂药的合理应用[J].中国药师,2005,8(6):510-512. 被引量:6
  • 3杨诗杰,苏汝好,项岚,乔海灵.降血脂药的应用现状及研究进展[J].医药论坛杂志,2006,27(1):90-92. 被引量:31
  • 4Noji Y,Higashikata T,Inazu A,et al.Long-term treatment with pitavastatin(NK-104),a new HMG-CoA reductise inhibitor of patients with heterozy-gous familial hypereholesterolemia[J].A The Rosclerosis,2010,163(1):157-164.
  • 5Zhou M S,Jaime E A,Raij L.Atorvastatin prevents end-organ injury in salt-sensitive hypertension[J].Hypertension,2009,44(2):186-190.
  • 6Ballantyne C M,Blazing M A,King T R,et al.Efficiency and safety of ezetimibe coadministered with simvastatin compared with atorvastatin in adults with hyperclolesterolemia[J].Am J Cardiol,2008,93(12):1 487-1 494.
  • 7Corti R,Fuster V,Fayad Z A,et al.Lipid lowering by simvastatin induces regression of human a the rosclerotic lesions two year′s follow-up by high resolution noninvasive magnetic resonance imaging[J].Circulation,2010,106(23):2 884-2 887.
  • 8Thompson P D,Ciarkson P,Karas R H.Statinassoci-atedmyopathy[J].JAMA,2010,289(13):1 681-1 690.
  • 9魏玉西,徐传金,赵爱云,刘蕾,艾桂花.海洋生物降血脂活性物质研究进展[J].中国生化药物杂志,2009,30(5):356-358. 被引量:7
  • 10徐婷,韩硕,林昭静,冯子峰.调脂药物的临床应用与研究进展[J].中国实用医药,2010,5(19):241-242. 被引量:8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部